Literature DB >> 24150266

How to substantially increase recruitment in cancer trials in New Zealand.

David Hadorn1, Nick Wilson, Richard Edwards, Tony Blakely, Diana Sarfati.   

Abstract

Recruitment rates into cancer treatment trials are generally very low, both in New Zealand and internationally. This viewpoint article suggests that recruitment rates could be substantially increased by considering all patients newly diagnosed with cancer to be automatically eligible for randomisation if experimental treatments were available under study protocols for patients with their type of cancer. Patients randomised to be offered the experimental treatment would be approached for consent to receive it, whereas patients randomised not to be offered this treatment would continue to receive standard treatment (thus serving as the control group) and not be approached for consent. Routine adoption of this approach, known as "post-randomisation consent" or "pre-randomisation", would require public consultation and "societal consent". While this proposal is not without significant challenges and potential disadvantages, an informed public discussion on the subject would seem worthwhile given the potential for increasing patient access to new cancer treatments and advancing medical science.

Entities:  

Mesh:

Year:  2013        PMID: 24150266

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  1 in total

1.  PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study.

Authors:  E J Bass; N Klimowska-Nassar; T Sasikaran; E Day; F Fiorentino; M R Sydes; M Winkler; N Arumainayagam; B Khoubehi; A Pope; H Sokhi; T Dudderidge; H U Ahmed
Journal:  Contemp Clin Trials       Date:  2021-06-15       Impact factor: 2.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.